UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AQST NASDAQ Global Market FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ C ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2019 Earnings Conference Call November 6, 2019 8:00 AM ET Company Participants Stephanie Carrington - Westwicke Investor Relations Keith Kendall - Chief Executive Officer John Maxwell - Chief Financial Officer Ken Marshall - Chief Commercial Officer Dan Barber - Senior Vice President & Chief Operating Officer Conference Call Participants Rafay Sardar - BMO Capital Markets Liana Moussatos - Wedbush Securities Jason Butler - JMP Securities Thomas Flaten - Lake Str ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AQST NASDAQ Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ t ...

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q2 2019 Earnings Conference Call August 7, 2019 8:00 AM ET Company Participants Lauren Walrath - Head, Corporate Marketing and Communications Keith Kendall - Chief Executive Officer John Maxwell - Chief Financial Officer Gary Slatko - Senior Vice President, Chief Medical Officer Ken Marshall - Chief Commercial Officer Dan Barber - Senior Vice President & Chief Operating Officer Conference Call Participants Ashley Ryu - RBC Capital Markets Liana Moussatos - Wedbush ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 30 Technology Dri ...